In a mounting legal confrontation, Texas Attorney General Ken Paxton has initiated a lawsuit against Johnson & Johnson and its subsidiary Kenvue. The lawsuit centers on claims that the companies deceptively marketed Tylenol to pregnant women without disclosing potential risks related to autism and attention-deficit hyperactivity disorder (ADHD). This action, filed in Panola County District Court, follows President Donald Trump’s advisories against the use of acetaminophen during pregnancy, despite ongoing scientific debates over any causal connection to neurological conditions. The detail on this lawsuit can be traced to JURIST.
The state’s complaint references at least 26 epidemiological studies suggesting a link between prenatal acetaminophen exposure and autism spectrum disorders. Such allegations targeting a widely consumed medication—reportedly used by approximately 65% of pregnant women—have provoked significant public health discussions.
Despite the claims in the lawsuit, the scientific community remains divided. A notable Swedish study involving 2.5 million children reported that any perceived link between acetaminophen and autism vanished upon closer scrutiny, particularly when comparing siblings where one was exposed to the medication during pregnancy and the other was not. This study, as shared by Nature, emphasizes the importance of accounting for confounding factors, such as maternal infections that might necessitate painkiller use.
Johnson & Johnson, through Kenvue, has vowed to contest the lawsuit, labeling the claims as scientifically unfounded. The company defends acetaminophen’s safety, citing endorsements from rigorous research and medical professionals. Additionally, the FDA has reviewed the evidence over a decade, consistently concluding that the data does not support a definitive causal link to autism.
Amid the ongoing litigation, the FDA announced under Trump’s administration that it would introduce new warning labels for acetaminophen, pointing to a “possible association” with neurological disorders, while acknowledging that a direct causal relationship has yet to be established.
Texas is aiming to impose civil penalties amounting to $10,000 per violation. The lawsuit not only scrutinizes the drug’s safety for pregnant women but also accuses Johnson & Johnson of fraudulently transferring liabilities to its spinoff, Kenvue, to sidestep potential damages. In a prior ruling, a federal judge dismissed similar lawsuits, indicating that the scientific evidence was unconvincing.
This complex legal battle has fueled discussions regarding corporate accountability and consumer safety, particularly concerning pregnant women. As these proceedings unfold, they could have significant implications for pharmaceutical litigation and public health policy.